Cholestech gets US thumbs-up for CRP test:
This article was originally published in Clinica
Executive Summary
The US FDA has given Cholestech 510(k) market clearance to add a high sensitivity C-reactive protein (hs-CRP) blood test to the menu of assays run on its LDX tabletop analyser. The test, the first immunoassay developed for use on the analyser, can help doctors assess arterial inflammation and risk of heart disease. Laboratories will be able to use the test on the LDX system following the completion of a simple software upgrade, says the Hayward, California firm. Cholesterol and liver enzyme tests are already available for use on the analyser.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.